» Articles » PMID: 32207274

Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus

Overview
Specialty Endocrinology
Date 2020 Mar 25
PMID 32207274
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study was conducted to compare glycaemic control with insulin detemir administered according to two titration algorithms (3-0-3 and 2-4-6-8) after 20 weeks of treatment in subjects with type 2 diabetes mellitus inadequately controlled on metformin.

Methods: This was a 20-week, randomised, multicentre, open-labelled, treat-to-target trial. Forty-six patients were randomised in a 1:1 manner to either the 3-0-3 (G3, =23) or 2-4-6-8 (G2, =23) algorithm. The primary endpoint was change of haemoglobin A1c (HbA1c), and the secondary safety endpoint included hypoglycaemic events.

Results: After 20 weeks, HbA1c decreased similarly in the G3 and G2 groups, with a mean change of -0.9% from baseline. The mean change in fasting plasma glucose was numerically similar in both groups. The hypoglycaemia event rate per 100-patient-years of exposure () in the G2 group (=1,427) was higher than that in the G3 group (=807).

Conclusion: Both treatment groups had numerically similar HbA1c reductions. A trend towards fewer hypoglycaemia episodes after dose stabilisation was seen with the simpler G3. Clinically, this may be an important observation, as a simpler titration algorithm may support self-management and maintenance of insulin therapy.

Citing Articles

Time for Using Machine Learning for Dose Guidance in Titration of People With Type 2 Diabetes? A Systematic Review of Basal Insulin Dose Guidance.

Thomsen C, Hangaard S, Kronborg T, Vestergaard P, Hejlesen O, Jensen M J Diabetes Sci Technol. 2022; 18(5):1185-1197.

PMID: 36562599 PMC: 11418255. DOI: 10.1177/19322968221145964.


Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials.

Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G BMJ Open Diabetes Res Care. 2020; 8(1).

PMID: 32636220 PMC: 7342431. DOI: 10.1136/bmjdrc-2020-001477.

References
1.
Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

2.
Hollander P, Raslova K, Skjoth T, Rastam J, Liutkus J . Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab. 2011; 13(3):268-75. DOI: 10.1111/j.1463-1326.2010.01351.x. View

3.
Jabbour S . Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?. Int J Clin Pract. 2008; 62(6):845-7. DOI: 10.1111/j.1742-1241.2008.01757.x. View

4.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

5.
Le Floch J, Levy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S . Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care. 2008; 32(1):32-7. PMC: 2606825. DOI: 10.2337/dc08-0332. View